NovoCure Limited
Price Action
Technical Summary
CONSOLIDATINGNovoCure Limited is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings contraction of 100% provides fundamental context to the price action. However, with RSI at 77, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $12.81 | +23.99% | ABOVE |
| 50 SMA | $12.44 | +27.65% | ABOVE |
| 100 SMA | $12.57 | +26.31% | ABOVE |
| 150 SMA | $12.63 | +25.71% | ABOVE |
| 200 SMA | $12.56 | +26.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NVCR in an uptrend right now?
NVCR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NVCR overbought or oversold?
NVCR's RSI (14) is 77. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is NVCR outperforming the market?
NVCR has a Relative Strength (RS) Rating of 80 out of 99. Yes, NVCR is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is NVCR in its 52-week range?
NVCR is trading at $15.88, which is 79% of its 52-week high ($20.06) and 59% above its 52-week low ($9.82).
How volatile is NVCR?
NVCR has a Beta of 2.20 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.